The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months. The main questions it aims to answer are:
* Does NTZ treatment of diarrheal Cryptosporidium infection lower the number of days of diarrhea?
* Does NTZ treatment of diarrheal and non-diarrheal Cryptosporidium infection lower the number of days that parasites can be found in the stool?
Researchers will compare NTZ to a placebo (a look-alike substance that contains no drug) to see if NTZ works to treat Cryptosporidium.
Participants will:
* Take NTZ or placebo for 3 days
* Receive regular visits from field research assistants
* Provide blood and urine samples

开始日期2025-05-01

申办/合作机构

Johns Hopkins Bloomberg School of Public Health

[+1]

NCT05157243

/ Withdrawn临床3期

Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes. Each participant will be followed for approximately 28 days.

开始日期2024-08-01

申办/合作机构

Romark, L.C.

NCT05157269

/ Withdrawn临床3期

Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.

开始日期2024-08-01

申办/合作机构

Romark, L.C.

100 项与硝唑尼特相关的临床结果

登录后查看更多信息

100 项与硝唑尼特相关的转化医学

登录后查看更多信息

100 项与硝唑尼特相关的专利（医药）

登录后查看更多信息

1,743

项与硝唑尼特相关的文献（医药）

2025-06-01·BIOORGANIC CHEMISTRY

Nitazoxanide and Umbelliferone improves Imiquimod-induced psoriasis in Balb/C mice

Article

作者: Borkar, Maheshkumar ; Purewal, Japneet Singh ; Doshi, Gaurav M

Signal Transducer and Activator of Transcription (STAT) 3 is a significant contributor to the development and pathogenesis of psoriasis (Pso). Research demonstrated STAT3 signalling to be upregulated in Pso. Additionally, Pso results in oxidative stress that activates various signalling pathways like factor nuclear kappa-B (NF-κB). Nitazoxanide (NTZ) is an antiprotozoal drug shown to inhibit the STAT3 pathway. Umbelliferone (UMB) is an antioxidant, and anti-inflammatory and can suppress NF-κB signalling. Therefore, we propose to hypothesize that NTZ and UMB would be effective in treating Pso. Balb/c mice were treated with IMQ to induce Pso. The clinical characteristics of Pso were assessed using the Psoriasis Area and Severity Index (PASI), back skin thickness, spleen length and mass, and histology of the skin sample tissue. In addition, we measured the levels of interleukin-17 (IL-17), tumor necrosis factor-α (TNF-α), STAT3, and NF-κB. Furthermore, to gain the interaction of NTZ and UMB with STAT3, a detailed in-silico study has been performed. The impact of treatment on oxidative stress was evaluated by estimating the activity of superoxide dismutase (SOD) and catalase (CAT). The results demonstrate that mice subjected to IMQ-induced Pso exhibited positive responses to treatment with NTZ and UMB. Additionally, IL-17, TNF-α levels, STAT3, and NF-κB were decreased in NTZ and UMB-treated groups. SOD and CAT levels in NTZ and UMB groups were elevated. Our findings show that NTZ and UMB are potential therapeutic medications for Pso.

2025-06-01·BIOCHIMIE

Nitazoxanide inhibits pili assembly by targeting BamB to synergize with polymyxin B against drug-resistant Escherichia coli

Article

作者: Gong, Jian ; Zhao, Yongshan ; Tuo, Jiale ; Li, Boyu ; Zhou, Hongmei ; Wang, Linwei ; Li, Wenwen ; Ji, Bingjie ; Du, Minghui

Gram-negative bacteria rely on pili assembly for pathogenicity, with the chaperone-usher (CU) pathway regulating pilus biogenesis. Nitazoxanide (NTZ) inhibits CU pathway-mediated P pilus biogenesis by specifically interfering with the proper folding of the outer membrane protein (OMP) usher, primarily mediated by the β-barrel assembly machinery (BAM) complex. In this study, we identified the BAM complex components BamB and the BamA POTRA2 domain as key binding targets for NTZ. Molecular dynamics simulations and Bio-Layer Interferometry revealed that BamB residues S61 and R195 are critical for NTZ binding. NTZ activated the Cpx two-component system and induced inner membrane perturbations, which resulted from the accumulation of misfolded P pilus subunits. Upregulation of the ibpAB gene, which protects the bacteria against NTZ-induced oxidative stress, was also observed. Importantly, NTZ combined with polymyxin B enhanced the latter's antibacterial activity against both susceptible and MCR-positive E. coli strains. This enhancement was achieved through NTZ-induced increases in inner membrane permeability, oxidative stress, and inhibition of efflux pump activity and biofilm formation. This study provides new insights into the antimicrobial mechanism of NTZ and highlights its potential as an antibiotic adjuvant by targeting BamB to inhibit the CU pathway, restoring the efficacy of polymyxin B against multidrug-resistant bacteria.

2025-05-01·PHYTOMEDICINE

Mitochondrial dynamics and metabolism in macrophages for cardiovascular disease: A review

Review

作者: Wang, Miao-Miao ; Li, Ji ; Jia, Cheng-Lin ; Zhong, Yi-Lang ; Cao, Yong-Bing ; Chen, Jian ; Liang, Zhi-Qiang ; Ma, Chao ; Xu, Chen-Qin

BACKGROUND:

Mitochondria regulate macrophage function, affecting cardiovascular diseases like atherosclerosis and heart failure. Their dynamics interact with macrophage cell death mechanisms, including apoptosis and necroptosis.

PURPOSE:

This review explores how mitochondrial dynamics and metabolism influence macrophage inflammation and cell death in CVDs, highlighting therapeutic targets for enhancing macrophage resilience and reducing CVD pathology, while examining molecular pathways and pharmacological agents involved.

STUDY DESIGN:

This is a narrative review that integrates findings from various studies on mitochondrial dynamics and metabolism in macrophages, their interactions with the endoplasmic reticulum (ER) and Golgi apparatus, and their implications for CVDs. The review also considers the potential therapeutic effects of pharmacological agents on these pathways.

METHODS:

The review utilizes a comprehensive literature search to identify relevant studies on mitochondrial dynamics and metabolism in macrophages, their role in CVDs, and the effects of pharmacological agents on these pathways. The selected studies are analyzed and synthesized to provide insights into the complex relationships between mitochondria, the ER, and Golgi apparatus, and their implications for macrophage function and fate.

RESULTS:

The review reveals that mitochondrial metabolism intertwines with cellular architecture and function, particularly through its intricate interactions with the ER and Golgi apparatus. Mitochondrial-associated membranes (MAMs) facilitate Ca2+ transfer from the ER to mitochondria, maintaining mitochondrial homeostasis during ER stress. The Golgi apparatus transports proteins crucial for inflammatory signaling, contributing to immune responses. Inflammation-induced metabolic reprogramming in macrophages, characterized by a shift from oxidative phosphorylation to glycolysis, underscores the multifaceted role of mitochondrial metabolism in regulating immune cell polarization and inflammatory outcomes. Notably, mitochondrial dysfunction, marked by heightened reactive oxygen species generation, fuels inflammatory cascades and promotes cell death, exacerbating CVD pathology. However, pharmacological agents such as Metformin, Nitazoxanide, and Galanin emerge as potential therapeutic modulators of these pathways, offering avenues for mitigating CVD progression.

CONCLUSION:

This review highlights mitochondrial dynamics and metabolism in macrophage inflammation and cell death in CVDs, suggesting therapeutic targets to improve macrophage resilience and reduce pathology, with new pharmacological agents offering treatment opportunities.

项与硝唑尼特相关的新闻（医药）

2025-03-19

·GlobeNewswire-Health Care

ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets

PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug (RLD) Alinia®. "The market launch of Nitazoxanide Tablets, another niche limited competition product, underscores our purpose of ‘Serving Patients, Improving Lives’,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "We share ANI’s commitment to providing affordable, high-quality medicines for the patients who depend on them and are pleased to partner on the launch of this limited competition product,” stated Dr. Jagadeesh Rangisetty, Chief Executive Officer of Biophore. U.S. annual sales for Nitazoxanide Tablets total approximately $36.1 million, based on December 2024 moving annual total (MAT) IQVIA data. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com. About Biophore India Pharmaceuticals Pvt. Ltd.Biophore, an established pharmaceutical company, is engaged in the development and manufacturing of niche, high quality pharmaceutical products for the generic industry. Since its inception in 2007, Biophore has emerged as a trusted partner for niche and complex products in the generic industry across US, Europe and other regulated markets. For more information, please visit our website, http://www.biophore.com/. Forward-Looking StatementsThis press release contains not only historical information, but also forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the Company’s expectations or beliefs concerning future events, including statements regarding the benefits of the acquisition of Alimera Sciences. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “continue,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “shall,” “would” other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of our approved products, including Cortrophin Gel, ILUVIEN and YUTIQ, to achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability; our ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all; the limitation of our cash flow as a result of the indebtedness and liabilities incurred from the recent acquisition of Alimera; the risks that our acquisitions and investments, including the recent acquisition of Alimera, could disrupt our business and harm our financial position and operating results; delays and disruptions in production of our approved products, increased costs and potential loss of revenues if we need to change suppliers due to the limited number of suppliers for our raw materials, active pharmaceutical ingredients, expedients, and other materials; delays and disruptions in production of our approved products as a result of our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel, ILUVIEN and YUTIQ; delays or failure in obtaining and maintaining approvals by the FDA of the products we sell; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies, and the focus of the current U.S. presidential administration, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions; risks that we may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of our products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the ability of our manufacturing partners to meet our product demands and timelines; the impact of changes or fluctuations in exchange rates; our ability to develop, license or acquire, and commercialize new products; our obligations in agreements under which we license, develop or commercialize rights to products or technology from third parties and our ability to maintain such licenses; the level of competition we face and the legal, regulatory and/or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products; our ability to protect our intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the impact of any litigation to which we are, or may become, a party; our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; our ability to maintain the services of our key executives and other personnel; and general business and economic conditions, such as inflationary pressures, geopolitical conditions including but not limited to the conflict between Russia and the Ukraine, the conflict in the Middle East, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies. More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: ANI Pharmaceuticals, Inc.

上市批准

2025-02-10

·GlobeNewswire-Health Care

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternativelyto pay a consent fee of EUR 0.60 per bond still outstanding after the upcoming bondholder meeting and cancellation of the repurchased 2025 OCEANEs Both proposals are subject to approval of the royalty financing by the 2025 OCEANEs bondholders at the upcoming bondholders meeting and closing of the royalty financing Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the final terms of the 2025 OCEANEs repurchase proposal and the consent fee that would be paid to the holders of 2025 OCEANEs still outstanding after cancellation of repurchased 2025 OCEANEs. Context On January 30, 2025, GENFIT announced that it has entered into a non-dilutive capped royalty financing agreement (the “Royalty Financing”) with HealthCare Royalty (HCRx) for up to €185 million. This transaction significantly extends GENFIT’s cash runway, including after the repayment of its bonds convertible into new shares and/or exchangeable into existing shares due October 16, 2025 (the “2025 OCEANEs”). GENFIT also announced that it intended to offer to interested bondholders to repurchase their 2025 OCEANEs. In the Royalty Financing, HCRx will be compensated and repaid out of a portion of the royalties which GENFIT is eligible to receive on sales of Iqirvo® (elafibranor) pursuant to its long-term strategic partnership with Ipsen. To secure its obligations under the Royalty Financing, GENFIT will transfer the corresponding royalty receivables to a French law trust (fiducie-sûreté) for the benefit of the holders of the royalty financing bonds. The terms and conditions of the 2025 OCEANEs contain a negative pledge clause which limits GENFIT’s ability to grant security interests to its creditors on its present or future assets or revenues. Granting the fiducie-sûreté is not permitted under this clause. The closing of the Royalty Financing (i.e. the payment of the first €130 million under the Royalty Financing) is thus conditioned upon the holders of the 2025 OCEANEs approving an amendment to the negative pledge clause (the “Amendment of Terms”). If the Amendment of Terms is approved1, and the closing of the royalty financing is completed, GENFIT will pay a consent fee (the “Consent Fee”) to the holders of 2025 OCEANEs still outstanding after cancellation of the repurchased 2025 OCEANEs. Concurrently with the Amendment of Terms, GENFIT is proposing to repurchase the 2025 OCEANEs of any interested holder (the “Repurchase” and, together with the Amendment of Terms, the “Transaction”). Dual Proposal to the 2025 OCEANEs holders GENFIT and Natixis, its Solicitation Advisor, have collected feedback from the 2025 OCEANEs holders in order to set the definitive terms of the Transaction. GENFIT proposes: to repurchase 2025 OCEANEs at a price of EUR 32.00 per bond, or alternativelyto pay a Consent Fee of EUR 0.60 per 2025 OCEANE In the coming days, GENFIT will propose to all of the 2025 OCEANEs holders to enter into a Put Option Agreement, pursuant to which GENFIT will unconditionally and irrevocably undertake to repurchase the 2025 OCEANEs of such holder, subject to approval by the general meeting of the 2025 OCEANEs holders of the Amendment of Terms and the closing of the Royalty Financing. After execution of the Put Option Agreement, the holder will have until several days after the closing of the Royalty Financing to exercise its option under the Agreement. Holders of the 2025 OCEANEs who have not entered into the Put Option Agreement or who do not exercise their option will receive the Consent Fee. As stated above, both the Repurchase and the payment of the Consent Fee are subject to (i) the approval by the general meeting of the 2025 OCEANEs holders of the Amendment of Terms, and (ii) the closing of the Royalty Financing. 2025 OCEANEs holders interested in the Repurchase are invited to contact (i) with respect to qualified investors, GENFIT at investors@genfit.com or their usual sales contact at Natixis (the “Solicitation Advisor”), or at ld-m-equityflowsalescb@natixis.com or at ld-secm-syndicateteam@natixis.com, and (ii) with respect to retail holders, the 2025 OCEANEs Bondholders Representative (Représentant de la Masse) at genfit@aetherfs.com. The Consent Fee will only be paid after the Repurchase has taken place. 2025 OCEANEs that have been bought back by GENFIT as part of the Repurchase (or that have been converted prior to 5:00 p.m. (Paris time) on the date falling 2 business days prior to the date of payment of the Consent Fee) will thus not receive the Consent Fee. The terms and conditions of the 2025 OCEANEs contain a clean-up call option at par if the total number of 2025 OCEANEs still outstanding represents 15% or less of the number of 2025 OCEANEs originally issued (that is 912,162 2025 OCEANEs or less, compared to 1,902,698 2025 OCEANEs outstanding as of today). GENFIT undertakes that, following the Repurchase, it will not exercise this clean-up call option until the 2025 OCEANEs reach maturity. In the coming days, GENFIT will convene a general meeting of the 2025 OCEANEs holders, which is expected to be held in early March. A Consent Solicitation Memorandum will be published, together with the documents required by French law. The results of the general meeting and the closing of the Royalty Financing will be announced in two subsequent press releases. Natixis is acting as sole solicitation advisor to assist GENFIT to seek the consent of the holders of the 2025 OCEANEs and in the repurchase of the 2025 OCEANEs. CMS Francis Lefebvre is acting as legal advisor to GENFIT. ABOUT GENFIT GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor2) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about the completion of the royalty financing and the timing of and the vote of the bondholders at the 2025 OCEANEs general meeting. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024, the Half-Year Business and Financial Report dated September 19, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors Tel: +33 3 2016 4000 | investors@genfit.com GENFIT | Media Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1 The required quorum is 1/4 of the outstanding 2025 OCEANEs and the required majority is 2/3 of the 2025 OCEANEs holders present or represented.2 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

2025-01-29

·GlobeNewswire-Health Care

GENFIT Announces 2025 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025. 2025 Financial Calendar February 27, 2025 Publication of revenue and cash position at December 31, 2024 April 24, 2025 Publication of Full Year 2024 financial statements The 2024 Universal Registration Document and Annual Financial Report (included in the Universal Registration Document), as well as the Annual Report on Form 20-F will be made public by the end of April 2025. May 22, 2025 Publication of revenue and cash position at March 31, 2025 June 17, 2025 Annual Shareholders Meeting September 22, 2025 Publication of the half-year 2025 financial statements November 20, 2025 Publication of revenue and cash position at September 30, 2025 This calendar is subject to change. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development: VS-01, NTZ, SRT-015, CLM-022 and VS-02-HE, based on complementary mechanisms of action using different routes of administration. Other assets target other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorder (UCD) and organic acidemia (OA). GENFIT's expertise in the development of high-potential molecules from early to advanced stages, and in pre-commercialization, was demonstrated in the accelerated approval of Iqirvo® (elafibranor1) by the U.S. Food and Drug Administration, the European Medicines Agency and the Medicines and Healthcare Regulatory Agency in the UK for Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis) and TS-01 focusing on blood ammonia levels. GENFIT is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Nasdaq Global Select Market and on the Euronext regulated market in Paris, Compartment B (Nasdaq and Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com FORWARD LOOKING STATEMENTS This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to GENFIT, including, but not limited to statements about GENFIT’s research and development programs and planned release of financial information. The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, potential commercial success of elafibranor if approved, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2023 Universal Registration Document filed on April 5, 2024 (no. D.24-0246) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (www.amf.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company’s 2023 Annual Report on Form 20-F filed with the SEC on April 5, 2024 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACTS GENFIT | Investors Tel: +33 3 2016 4000 | investors@genfit.com GENFIT | Media Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com 1 Elafibranor is marketed and commercialized in the U.S by Ipsen under the trademark Iqirvo®. Attachment GENFIT Announces 2025 Financial Calendar

加速审批财报

100 项与硝唑尼特相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02486	硝唑尼特	P01AX11	DB00507

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
隐孢子虫病	美国	Romark, L.C.	2002-11-22
腹泻	美国	Romark, L.C.	2002-11-22
贾第虫病	美国	Romark, L.C.	2002-11-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	美国	Romark, L.C.	2020-05-13
新型冠状病毒感染	临床3期	美国	Romark, L.C.	2020-05-12
病毒性呼吸道感染	临床3期	美国	Romark, L.C.	2020-05-12
普通感冒	临床3期	美国	Romark, L.C.	2018-09-11
普通感冒	临床3期	波多黎各	Romark, L.C.	2018-09-11
肠道病毒感染	临床3期	美国	Romark, L.C.	2018-09-11
肠道病毒感染	临床3期	波多黎各	Romark, L.C.	2018-09-11
鼻病毒感染	临床3期	美国	Romark, L.C.	2018-09-11
鼻病毒感染	临床3期	波多黎各	Romark, L.C.	2018-09-11
乙型流感病毒感染	临床3期	美国	Romark, L.C.	2015-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04489381 (CTgov)	临床3期	鼻病毒感染 \| 普通感冒 \| 肠道病毒感染	214	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	鏇醖鑰觸衊積簾範糧蓋(鑰憲憲醖鹹築製簾餘鏇) = 壓艱觸遞廠構遞衊廠選顧願製網襯醖鑰艱廠壓 (餘範鑰選鬱鏇願繭醖遞, 觸鹹憲膚窪簾顧膚網憲 ~ 膚願選窪壓遞簾積衊鏇) 更多	-	2024-10-17
				Placebo (Placebo)	鏇醖鑰觸衊積簾範糧蓋(鑰憲憲醖鹹築製簾餘鏇) = 構顧願觸窪繭顧築鑰糧顧願製網襯醖鑰艱廠壓 (餘範鑰選鬱鏇願繭醖遞, 鑰窪遞製構範壓壓獵鹽 ~ 鏇衊鬱艱憲醖鹽簾醖遞) 更多
UEGW2024	N/A	感染	-	Levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL)	艱獵壓鹽選夢選醖糧願(觸醖顧襯廠顧壓顧憲膚) = 蓋窪鹹簾憲廠簾艱願獵範壓夢遞積築衊壓襯願 (鑰獵選糧鬱網齋餘鏇觸, 75.73 ~ 91.27)	-	2024-10-13
				Moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL)	艱獵壓鹽選夢選醖糧願(觸醖顧襯廠顧壓顧憲膚) = 艱範鏇積糧鏇積積選壓範壓夢遞積築衊壓襯願 (鑰獵選糧鬱網齋餘鏇觸, 73.57 ~ 90.01)
NCT04343248 (CTgov)	临床3期	新型冠状病毒感染 \| 病毒性呼吸道感染	190	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	鑰襯窪醖築憲鑰壓顧糧 = 齋蓋鏇製獵襯衊齋選壓淵襯夢糧窪齋襯顧網蓋 (願獵襯製蓋簾鑰網築艱, 糧窪襯膚醖選網窪夢積 ~ 憲範蓋鏇壓糧窪網製襯) 更多	-	2024-07-08
				Placebo (Placebo)	鑰襯窪醖築憲鑰壓顧糧 = 壓鹹廠簾顧醖蓋網網願淵襯夢糧窪齋襯顧網蓋 (願獵襯製蓋簾鑰網築艱, 製艱鬱獵簾夢鑰醖積醖 ~ 蓋壓艱廠餘願顧醖憲鏇) 更多
NCT04359680 (CTgov)	临床3期	新型冠状病毒感染 \| 新冠肺炎后遗症 \| 病毒性呼吸道感染	1,407	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	積醖遞鹽鹽憲艱選繭獵 = 繭糧獵夢襯壓構鹹糧築醖鏇壓鹽窪範繭範醖醖 (願衊觸廠鏇遞網鏇衊糧, 獵範膚選願遞繭窪築蓋 ~ 艱齋鑰襯鏇繭製鹹構憲) 更多	-	2024-06-26
				Placebo (Placebo)	積醖遞鹽鹽憲艱選繭獵 = 淵蓋鑰繭顧觸糧鹽鏇簾醖鏇壓鹽窪範繭範醖醖 (願衊觸廠鏇遞網鏇衊糧, 窪憲餘繭廠蓋範鹹繭築 ~ 簾網獵夢壓鹽餘築願夢) 更多
NCT04486313 (CTgov)	临床3期	新型冠状病毒感染	935	Vitamin Super B-Complex+Nitazoxanide (Nitazoxanide)	鹹衊遞窪選繭醖鏇簾築(鹹獵艱鑰鏇獵願夢築糧) = 衊餘獵範蓋築膚選鏇淵選選築構壓選夢膚齋醖 (膚窪鏇衊夢鏇衊壓簾觸, 製製選淵繭顧衊網網衊 ~ 憲鹽廠鹽廠醖鑰壓製網) 更多	-	2024-03-29
				Placebo (Placebo)	鹹衊遞窪選繭醖鏇簾築(鹹獵艱鑰鏇獵願夢築糧) = 糧鏇鹽範獵構觸壓獵鬱選選築構壓選夢膚齋醖 (膚窪鏇衊夢鏇衊壓簾觸, 醖簾艱遞範鏇醖築齋憲 ~ 築壓醖製蓋獵壓構淵製) 更多
NCT03905655 (CTgov)	临床2期	慢性乙型肝炎	51	Placebo Oral Tablet (Group 1)	襯膚選醖願壓遞鑰餘積(餘鏇積顧艱艱衊選壓積) = 遞鑰獵網廠餘廠簾膚襯壓衊製願壓襯憲淵艱製 (憲齋積鹽醖遞製選蓋鬱, 0.13) 更多	-	2023-11-07
				Placebo Oral Tablet+Nitazoxanide (Group 2)	襯膚選醖願壓遞鑰餘積(餘鏇積顧艱艱衊選壓積) = 膚觸糧蓋簾製鏇鹹構夢壓衊製願壓襯憲淵艱製 (憲齋積鹽醖遞製選蓋鬱, 0.90) 更多
NCT03395405 (CTgov)	临床2期	胃肠炎	31	Nitazoxanide (Nitazoxanide (500 mg))	積築鬱鬱獵艱願選醖廠(淵網鹽膚廠遞簾膚顧範) = 獵壓鑰廠構窪網鏇襯顧範衊餘顧餘衊醖淵衊淵 (艱鏇鏇膚簾構鬱鹽醖獵, 願醖憲觸積選網窪蓋壓 ~ 繭積遞願廠鹹壓窪遞膚) 更多	-	2022-10-24
				placebo (Placebo)	積築鬱鬱獵艱願選醖廠(淵網鹽膚廠遞簾膚顧範) = 鑰醖廠鹹憲餘衊衊獵觸範衊餘顧餘衊醖淵衊淵 (艱鏇鏇膚簾構鬱鹽醖獵, 蓋窪淵夢醖糧淵遞淵獵 ~ 廠範膚膚壓齋繭鑰憲鑰) 更多
EASL2022	N/A	慢加急性肝衰竭	-	Nitazoxanide 100 mg/kg	廠衊膚鑰膚選獵餘艱選(廠網選鬱鏇夢廠積鑰餘) = 鹹範憲製願願願範窪觸壓繭鹹淵顧範糧淵膚選 (網醖醖顧淵鑰獵憲鬱膚 ) 更多	积极	2022-06-23
				Vehicle	廠衊膚鑰膚選獵餘艱選(廠網選鬱鏇夢廠積鑰餘) = 襯觸糧餘繭鑰觸願餘簾壓繭鹹淵顧範糧淵膚選 (網醖醖顧淵鑰獵憲鬱膚 ) 更多
NCT04605588 (TriACT, CTgov)	临床2期	新型冠状病毒感染	7	Hydroxychloroquine+Nitazoxanide+ribavirin (Active Study Drug)	願壓顧顧艱鏇膚糧觸襯(淵鬱繭膚鏇範積鬱鏇蓋) = 顧範艱顧鹹蓋鏇積齋選願蓋壓選積襯獵構築築 (顧獵衊齋網網膚艱鹽糧, 觸鑰製淵鏇醖鹹膚鏇鹽 ~ 餘遞醖繭鹹顧簾顧顧願) 更多	-	2022-05-05
				Placebo Hydroxychloroquine (Placebo)	願壓顧顧艱鏇膚糧觸襯(淵鬱繭膚鏇範積鬱鏇蓋) = 齋鹽淵構鑰壓觸淵選夢願蓋壓選積襯獵構築築 (顧獵衊齋網網膚艱鹽糧, 糧糧鏇鏇築窪衊鹹醖鏇 ~ 鑰艱選壓齋鑰壓糧糧築) 更多
NCT04486313 (Pubmed) 人工标引	临床3期	新型冠状病毒感染	1,092	nitazoxanide	蓋鑰遞遞鹽襯製廠構膚(鏇艱壓鏇壓鹽壓醖觸範) = 齋淵糧醖積鏇繭膚築觸齋積觸選獵選鑰顧遞艱 (齋顧觸積製簾襯鹽鑰願, 6.3) 更多	不佳	2022-02-28
				Placebo	蓋鑰遞遞鹽襯製廠構膚(鏇艱壓鏇壓鹽壓醖觸範) = 糧衊壓範繭獵構餘艱壓齋積觸選獵選鑰顧遞艱 (齋顧觸積製簾襯鹽鑰願, 7.2) 更多